Coronavirus Vaccine Study Expands Participants and Diversity

Germany based BioNTech SE and Pfizer announced on September 12, 2020, they have submitted a request to expand the enrollment of their Phase 3 pivotal vaccine trial for BNT162b2, to up to 44,000 participants, and increase the study's diversity to include adolescents as young as 16 years of age and people with chronic, stable HIV, Hepatitis C, or Hepatitis B infection.